Ratings Lyra Therapeutics, Inc.

Equities

LYRA

US55234L1052

Real-time Estimate Cboe BZX Other stock markets 02:37:33 2024-05-17 pm EDT			5-day change	1st Jan Change
0.385 ^USD	+4.73%		+3.22%	-92.66%

May. 07	Jefferies Downgrades Lyra Therapeutics to Hold, Price Target at $0.50	MT
May. 07	HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
LYRA THERAPEUTICS, INC.	-92.66%	22.41M	C
MODERNA, INC.	+32.99%	50.85B	B-
IQVIA HOLDINGS INC.	+0.07%	42.82B	B
LONZA GROUP AG	+49.62%	42.03B	A
CELLTRION, INC.	-4.96%	29.55B	C
ICON PUBLIC LIMITED COMPANY	+10.53%	26.11B	B-
ALNYLAM PHARMACEUTICALS, INC.	-22.18%	19.13B	B
BIO-TECHNE CORPORATION	+8.48%	13.05B	B+
MEDPACE HOLDINGS, INC.	+27.15%	12.16B	C+
UNITED THERAPEUTICS CORPORATION	+24.65%	12.08B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes